Literature DB >> 6185584

Type-specific delayed hypersensitivity and protective immunity induced by isolated herpes simplex virus glycoprotein.

R D Schrier, L I Pizer, J W Moorhead.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6185584

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  27 in total

1.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.

Authors:  G Kümel; H C Kaerner; M Levine; C H Schröder; J C Glorioso
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

3.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Different forms of membrane-associated herpes simplex virus glycoproteins induce functionally distinct subsets of herpes simplex virus-specific suppressor T cells.

Authors:  G Y Ishioka; L I Pizer; J W Moorhead
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

5.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

7.  The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.

Authors:  H Ghiasi; D C Roopenian; S Slanina; S Cai; A B Nesburn; S L Wechsler
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

8.  Structural properties and reactivity of N-terminal synthetic peptides of herpes simplex virus type 1 glycoprotein D by using antipeptide antibodies and group VII monoclonal antibodies.

Authors:  D L Bosch; H J Geerligs; W J Weijer; M Feijlbrief; G W Welling; S Welling-Wester
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

9.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Necrotizing chorioretinitis in mice inoculated with herpes simplex virus type 1 with or without glycoprotein C: anterior chamber-associated immune deviation does not persist.

Authors:  Y Liu; H Minagawa; Y Toh; Y Sakai; T Ishibashi; H Inomata; R Mori
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.